Latest studies
- RecruitingPhase IV
A clinical trial to find out the best management of the bacteria called Staphylococcus aureus infection in the blood. A randomised clinical trial. Staphylococcus aureus Network Adaptive Platform trial (SNAP)
This hospital trial looks for the best ways to treat severe blood infections caused by Staphylococcus aureus bacteria. Researchers are testing standard, approved antibiotics, checking if patients can safely switch from a drip to tablets sooner, and seeing if body scans help doctors tailor treatment more effectively.
Staphylococcus aureus bacteraemiaNew Zealand - RecruitingPhase III
A Phase III trial of inhaled mosliciguat in pulmonary hypertension associated with interstitial lung disease
This clinical trial is testing an inhaled medicine called mosliciguat for people with high blood pressure in the lungs caused by lung scarring. Researchers want to see if breathing in this drug helps people walk further over six minutes compared to a dummy inhaler with no active medicine.
Pulmonary hypertension associated with interstitial lung diseaseNew Zealand - CompletedNot Applicable
LOTUS: LOng-Term follow-Up Study of triple-negative breast cancer
The LOTUS study is looking at the long-term health of people with triple-negative breast cancer who previously took part in a trial called BEATRICE. Researchers want to understand how past treatments affect health over many years, helping doctors improve care and support for future patients.
Triple-negative breast cancerNew Zealand - CompletedPhase I
Testing a potential new treatment for patients with severe alcohol-associated hepatitis called SZN-043
This study tests a new medicine called SZN-043 for people in hospital with severe alcohol-related hepatitis, an inflamed liver caused by alcohol. Doctors want to see how safe the drug is, how the body handles it, and if it could help damaged liver cells heal.
Severe alcohol-associated hepatitisNew Zealand - RecruitingPhase II
A study to learn if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet
This study is testing a new capsule called ZED1227 for adults with coeliac disease. Researchers want to see if this medicine can protect the gut and ease lingering tummy symptoms caused by accidental gluten exposure, even in people who already follow a strict gluten-free diet.
Coeliac diseaseNew Zealand - RecruitingPhase I/II
A trial looking at different treatments for neuroblastoma which has come back after initial therapy
The BEACON2 trial is testing new combinations of cancer medicines for children and young people whose neuroblastoma has returned or worsened after initial treatment. The goal is to find out which drug combinations are safest and work best to control the disease and improve future care.
Relapsed NeuroblastomaNew Zealand - Active not recruitingPHASE2
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
This study is testing a new medicine, BI 3034701, to see if it helps adults with obesity or overweight lose weight. Participants will get either the medicine or dummy medicine, plus advice on diet and exercise.
ObesityOverweightNew Zealand - Active not recruitingPHASE2
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
This study looks at giving olaparib, a new drug, before surgery and chemotherapy for recurrent ovarian, primary peritoneal, or fallopian tube cancer. It aims to see if it can shrink tumours and improve outcomes.
Ovarian CancerFallopian Tube CancerNeoadjuvant TreatmentDebulking Surgical ProceduresNew Zealand - RecruitingPhase II/III
Optimising therapy in FLT3-mutated acute myeloid leukaemia
This clinical trial looks at the best chemotherapy combinations for people newly diagnosed with acute myeloid leukaemia (AML) who have a specific gene change called FLT3. It compares current standard treatment with two new drug mixtures to see which clears the cancer best and prevents it from returning.
Acute myeloid leukemiaNew Zealand - Recruiting
Quality of Pediatric Resuscitation in a Multicenter Collaborative
This study looks at how the quality of CPR given to children during a cardiac arrest affects their recovery. Researchers are observing children in hospitals to see if better CPR techniques and after-care improve survival and brain function.
Cardiac ArrestCardiopulmonary ArrestNew Zealand - Recruiting
Optimal personalised treatment of early breast cancer using multiparameter analysis
This study looks at whether a specialised tumour test can help women with early breast cancer safely avoid chemotherapy. Researchers want to see if hormone therapy alone works just as well for some women, sparing them difficult side effects without increasing the risk of their cancer returning.
Breast cancerNew Zealand - RecruitingPhase III
Phase 3, randomised, double-blind, placebo- controlled, 3-arm study to investigate the safety and efficacy of efimosfermin alfa in participants with biopsy-confirmed F2- or F3-stage metabolic dysfunction-associated steatohepatitis (MASH) (ZENITH-1)
This clinical trial is testing a new injection called efimosfermin alfa for people with metabolic dysfunction-associated steatohepatitis (MASH), an inflamed fatty liver condition. Researchers want to see if monthly injections over four years can safely reduce liver fat, ease inflammation, and improve liver scarring compared to a dummy treatment.
Medical condition: Metabolic Dysfunction-Associated Steatohepatitis (MASH) Medical condition in lay language: Metabolic Fatty Liver Inflamation Therapeutic areas: Diseases [C] - Nutritional and Metabolic Diseases [C18]New Zealand - CompletedPhase III
MyeChild 01: Treating children with acute myeloid leukaemia
MyeChild 01 is a clinical trial for children and young people with acute myeloid leukaemia (AML). It tests whether adding a targeted drug called gemtuzumab ozogamicin to standard chemotherapy helps clear leukaemia cells more effectively and safely. It also looks at the best chemotherapy combinations before a stem cell transplant.
Acute myeloid leukaemiaNew Zealand - CompletedPhase III
A randomized trial of armpit (axilla) treatment for women with early stage breast cancer. POSNOC - POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy.
The POSNOC trial looks at the best way to treat the armpit in women with early breast cancer. If cancer is found in one or two armpit glands, researchers want to see if standard drug therapies alone work just as well as having extra armpit surgery or radiotherapy.
Breast cancerNew Zealand - Active not recruitingPHASE3
Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)
This study is testing a medicine called viltolarsen for boys with Duchenne muscular dystrophy who can still walk. It is an extension study for children who already completed an earlier trial. Every participant receives the medicine through a weekly drip for nearly two years to check its safety and long-term effects.
Duchenne Muscular DystrophyNew Zealand - RecruitingPHASE3
Phase 3 Trial of Reltodecacog Alfa (VMX-C001) vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.
This study looks at a new medicine, VMX-C001, for people taking blood thinners (FXa DOACs) who need urgent surgery. The goal is to see if VMX-C001 helps stop bleeding effectively during the operation compared to usual care. Experts will check how well bleeding is controlled.
Blood Loss, SurgicalCoagulation DisorderNew Zealand - Active not recruitingPHASE2
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
This study is looking at a new combination treatment, JNJ-78934804, for people aged 18-65 with Crohn's disease that is moderate to severe. It compares this new treatment to existing medicines, guselkumab and golimumab, to see how well it works over 48 weeks.
Crohn's DiseaseNew Zealand - RecruitingPHASE3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study compares two treatments for multiple myeloma that has come back or not responded to previous treatments. It looks at a new drug, mezigdomide, combined with standard medicines (bortezomib and dexamethasone), against another combination (pomalidomide, bortezomib, and dexamethasone). The aim is to see which combination is more effective and safe.
Relapsed or Refractory Multiple MyelomaNew Zealand - Active not recruitingPHASE3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
This study is testing a new medicine, BLU-5937, for adults in the UK with a long-lasting cough that hasn't responded to other treatments. It aims to see if the medicine can reduce how often people cough over 24 weeks, compared to a dummy pill.
CoughRefractory Chronic CoughNew Zealand - Enrolling by invitationPHASE3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
This study looks at a new treatment called Selatogrel for people who have recently had a heart attack and are at risk of another. It checks if taking Selatogrel when symptoms start can help prevent a second heart attack.
Acute Myocardial InfarctionNew Zealand - Active not recruitingPHASE3
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
This study looks at a new personalised treatment, Intismeran Autogene, combined with Pembrolizumab for high-risk melanoma. It aims to see if this combination can stop cancer from coming back better than Pembrolizumab alone after surgery, focusing on safety and effectiveness.
MelanomaNew Zealand - RecruitingPHASE3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
This study compares a new medicine called nemtabrutinib with existing treatments (ibrutinib or acalabrutinib) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. The aim is to see if the new drug is as good or better.
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaNew Zealand - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
This study looks at a new drug, pembrolizumab, for early-stage breast cancer. It's for people with a specific type of breast cancer (ER+/HER2-). Researchers want to see if adding pembrolizumab to standard chemotherapy and hormone therapy works better than standard treatment alone.
Breast CancerNew Zealand - Active not recruitingPHASE2
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
This study is testing new medicines, daplusiran/tomligisiran (DAP/TOM) and bepirovirsen, for people with long-term Hepatitis B. It aims to find the best dose of DAP/TOM to use with bepirovirsen to improve treatment.
Chronic Hepatitis B Virus InfectionHepatitis BNew Zealand - Active not recruitingPHASE3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
This study looks at a new medicine, BI 690517, combined with empagliflozin, for adults with chronic kidney disease. It aims to see if this combination can help slow down kidney disease progression and protect the heart, for people with and without type 2 diabetes.
Kidney Disease, ChronicNew Zealand - Active not recruitingPHASE3
Atrasentan in Patients With IgA Nephropathy
This study is testing a new medicine, atrasentan, for people with a kidney disease called IgA nephropathy. It compares atrasentan to a dummy pill (placebo) to see if it can slow down kidney damage and improve kidney function.
IgA NephropathyImmunoglobulin A NephropathyNew Zealand - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesNew Zealand - RecruitingPHASE3
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
This study is looking into the long-term safety of a new medicine called dazodalibep for people with Sjögren's Syndrome. It involves individuals who have already taken part in previous studies of this medicine.
Sjögren's SyndromeNew Zealand - RecruitingPHASE3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
This study looks at a new treatment called intismeran autogene, given with pembrolizumab, after surgery for non-small cell lung cancer. We want to see if this combination stops the cancer from coming back compared to pembrolizumab alone.
Carcinoma, Non-Small-Cell LungNew Zealand - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseNew Zealand - Active not recruitingPHASE3
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
This study looks at whether a new medicine, retatrutide, can help adults with obesity who also have heart disease or kidney problems. It aims to see if the medicine can reduce serious heart issues or stop kidney problems from getting worse.
Atherosclerotic Cardiovascular Disease (ASCVD)Chronic Kidney Disease (CKD)New Zealand - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
CancerNew Zealand - RecruitingPHASE3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
This study is looking into a new treatment called GB-0895 for teenagers and adults with severe asthma that isn't well-controlled by usual medicines. Participants will receive either GB-0895 or a dummy treatment over about a year to see if it improves their health.
Severe AsthmaNew Zealand - RecruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
This study is testing a new drug, daraxonrasib, for people with a specific type of advanced lung cancer (non-small cell lung cancer, or NSCLC) that has a RAS gene change. It compares the new drug to an existing chemotherapy, docetaxel, to see if it works better or has fewer side effects.
NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNSCLCNSCLC (Non-small Cell Lung Carcinoma)New Zealand - Active not recruitingPHASE3
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
This study looks at a new combination of medicines for postmenopausal women with a certain type of breast cancer. It tests if abemaciclib with standard hormone therapy works better than hormone therapy alone.
Breast CancerNew Zealand - Active not recruitingPHASE2
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
This study is for people with cancer that has spread, who are already benefiting from a specific medicine called trastuzumab emtansine (T-DM1) or other similar treatments in an earlier study. It allows them to keep receiving these important treatments for longer to see if they continue to help.
Neoplasm MetastasisNew Zealand - Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
This study looks at how well Medtronic heart devices, like pacemakers and defibrillators, perform over a long time. It helps ensure these devices are reliable and safe for people with heart conditions such as irregular heartbeats or heart failure.
ArrhythmiaBradycardiaHeart FailureSinus TachycardiaNew Zealand - Active not recruitingPHASE3
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
This study compares a new drug, pirtobrutinib, with existing approved treatments for people with a type of blood cancer called mantle cell lymphoma (MCL). It's for patients who have already had at least one treatment and are looking for other options.
Lymphoma, Mantle-CellNew Zealand - Active not recruitingPHASE3
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
This study is looking at a new treatment combination for a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL). It combines a new drug, tafasitamab, and another drug, lenalidomide, with standard chemotherapy to see if it works better than chemotherapy alone.
Diffuse Large B-cell LymphomaNew Zealand - RecruitingPHASE3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
This study is looking into a new drug, PF-06821497, combined with an existing drug, enzalutamide, for men with advanced prostate cancer. It wants to see if this combination works better than enzalutamide alone for those who haven't had certain other treatments.
Metastatic Castration-Resistant Prostate CancerNew Zealand - RecruitingPHASE3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
This study looks at new ways to treat multiple myeloma. Researchers are testing a drug called elranatamab, alone and with daratumumab, against a standard treatment. The aim is to find better and safer treatments for people who have tried other medicines.
Multiple MyelomaNew Zealand - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
This study is testing a new combination of medicines, Giredestrant and Palbociclib, for advanced breast cancer. It's for people whose cancer is hormone-sensitive (ER-positive) but not HER2-positive. Researchers want to see if this new combination works better and is safer than a standard treatment.
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerNew Zealand - Active not recruitingPHASE3
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
This study looks at a new drug, upadacitinib, for moderate to severe Hidradenitis Suppurativa (HS). It's for adults and teenagers whose HS hasn't improved with other treatments. We'll check if it's safe and helps reduce HS symptoms.
Hidradenitis SuppurativaNew Zealand - Active not recruitingPHASE2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
This study is for people with advanced solid cancers that haven't responded to other treatments. It uses a "precision medicine" approach, matching treatments to the specific genetic changes found in each person's tumour, aiming for more effective and personalised care.
Solid TumorsNew Zealand - RecruitingPHASE1, PHASE2
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
This study, FaR-RMS, is for children and adults with a type of cancer called rhabdomyosarcoma. It's looking for better ways to treat both newly diagnosed and returning cancer, using different combinations of medicines and radiotherapy.
RhabdomyosarcomaNew Zealand - Active not recruitingPHASE3
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
This study looks at a new medicine called risankizumab for Crohn's disease. We're checking how well it works and if it's safe for people who have already started treatment. It's like a follow-up to see how different doses work and how people feel over time.
Crohn's DiseaseNew Zealand - RecruitingPHASE3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
This study looks at a new medicine called survodutide for adults with a liver condition called MASH and moderate to advanced liver damage. It aims to see if the medicine can improve liver health and how safe it is.
Metabolic Dysfunction Associated Steatohepatitis (MASH)Liver FibrosisNew Zealand - RecruitingPHASE3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
This study looks at a new drug, mevrometostat, combined with enzalutamide for men with prostate cancer that has spread. It compares this combination to enzalutamide alone, to see if it works better for those not yet treated with specific hormone therapies.
Metastatic Castration Sensitive Prostate Cancer (mCSPC)Hormone Sensitive Prostate CancerProstate CancerCancer of the ProstateNew Zealand - RecruitingPHASE3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
This study is testing a new medicine, Opevesostat, for men with prostate cancer that has spread and is resistant to hormone treatment. We want to see if Opevesostat helps men live longer compared to standard hormone therapies, especially after they've had other treatments.
Prostate Cancer MetastaticNew Zealand - Active not recruitingPHASE3
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
This study offers continued access to treatments like Avelumab for people who were in earlier Pfizer studies and are still benefiting. It focuses on several cancers and ensures ongoing care and tracking of their health.
Advanced MalignanciesNSCLCOvarian CancerUrothelial CancerNew Zealand